Stock listing

Hamburg:471A aTyr Pharma, Inc. Aktie

German listing (Hamburg) of aTyr Pharma, Inc. · home listing NASDAQ:ATYR

Follow aTyr Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ATYR

$3.82 USD -0.26 (-6.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ATYR

Past year -85.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.80 – $4.15 USDNov 20, 2026
Volume
90,514 sharesNov 20, 2026
Market cap
$9.74M USDAt the close on Nov 20, 2026 · price × 2.55M shares outstanding
52-week range
$3.80 – $44.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$214,862 USDMedian day 1,131 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
aTyr Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ATYR · Home$3.82 USD-0.26 (-6.4%)90,514$3.85$4.15$3.80$4.08Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ATYR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.82-0.26-6.4%$3.85$4.15$3.8090,514
$4.08-0.91-18.2%$4.98$5.07$4.08117,857
$4.99-0.25-4.8%$5.31$5.41$4.70125,274
$5.24-0.865-14.2%$5.99$6.045$5.2438,748
$6.105-0.105-1.7%$6.24$6.535$5.95738,009
$6.21-0.56-8.3%$6.63$6.63$6.1935,142
$6.77-0.79-10.4%$7.65$7.65$6.70346,675
$7.56-0.02-0.3%$7.41$7.96$7.001113,223
$7.58+1.23+19.4%$6.29$7.785$5.93185,100
$6.35+0.32+5.3%$5.70$6.64$5.7069,400
$6.03-0.15-2.4%$6.13$6.22$5.6059,600
$6.18-0.45-6.8%$6.84$6.987$5.30152,100
$6.63+0.34+5.4%$6.33$7.22$6.11229,500
$6.29+1.35+27.3%$5.03$6.42$5.03334,900
$4.94-0.43-8.0%$5.32$5.429$4.32120,200
$5.37+0.25+4.9%$4.83$5.60$4.81227,600
$5.12+0.16+3.2%$4.80$5.20$4.6485,545
$4.96-1.176-19.2%$4.868$5.10$4.0685,348
$6.136-0.468-7.1%$6.60$6.668$5.7522,057
$6.604-0.196-2.9%$6.812$6.88$6.40813
$6.80-0.092-1.3%$6.80$7.184$6.72650
$6.892-0.04-0.6%$6.92$7.188$6.824772
$6.932+0.064+0.9%$6.836$7.112$6.612826
$6.868-0.092-1.3%$7.196$7.36$6.601,319
$6.96-0.392-5.3%$7.56$7.644$6.961,137
$7.352+0.02+0.3%$7.60$7.88$7.3521,391
$7.332-0.712-8.9%$8.00$8.288$7.2281,608
$8.044-0.548-6.4%$8.80$8.80$8.001,654
$8.592-1.256-12.8%$9.908$9.996$8.5921,266
$9.848-0.364-3.6%$10.21$10.36$9.84625
$10.21-0.92-8.3%$10.80$10.92$10.001,720
$11.13-0.204-1.8%$11.16$11.55$10.88701
$11.34-0.264-2.3%$11.60$11.82$11.22639
$11.60+0.112+1.0%$11.33$11.76$10.601,131
$11.49-0.276-2.3%$11.49$11.84$11.261,238
$11.76-0.356-2.9%$12.20$12.41$11.601,372
$12.12-0.188-1.5%$12.33$12.80$12.001,127
$12.31+0.40+3.4%$11.67$12.72$10.882,408
$11.91-0.292-2.4%$11.74$12.64$11.662,583
$12.20-1.304-9.7%$12.37$12.66$11.285,225
$13.50-1.504-10.0%$16.17$16.30$12.9681,325
$15.01+0.752+5.3%$14.40$15.20$14.00749
$14.26-0.656-4.4%$15.26$15.26$14.04835
$14.91+0.392+2.7%$15.20$15.20$14.74574
$14.52-0.54-3.6%$14.80$15.52$14.40793
$15.06-0.304-2.0%$15.80$15.92$14.80628
$15.36-0.204-1.3%$15.83$15.83$15.15596
$15.57+0.024+0.2%$15.76$16.03$15.00663
$15.54-1.648-9.6%$16.80$17.36$15.281,082
$17.19-0.084-0.5%$17.42$17.86$16.87891
$17.28-0.94-5.2%$18.76$18.78$17.20577
$18.22-1.016-5.3%$19.20$19.44$18.02519
$19.23-0.66-3.3%$20.40$20.40$19.20396
$19.89-0.248-1.2%$19.60$20.32$19.49159
$20.14+0.42+2.1%$20.20$20.36$19.20241
$19.72+0.66+3.5%$19.28$20.36$19.28438
$19.06-2.208-10.4%$21.20$21.34$19.00733
$21.27-0.332-1.5%$21.60$21.72$20.04640
$21.60-0.584-2.6%$22.40$22.60$21.20166
$22.18+0.144+0.7%$22.48$22.48$21.78184
$22.04-0.76-3.3%$22.90$22.90$21.24191
$22.80+1.60+7.5%$21.54$22.80$21.29423
$21.20+1.14+5.7%$20.42$21.36$19.60431
$20.06-0.06-0.3%$20.40$21.36$20.01327
$20.12-1.192-5.6%$20.67$20.96$20.00479

Splits

2 splits since 2019 · NASDAQ:ATYR · every price before a split is adjusted for it

DayRatioWhat
1-for-40Consolidation
1-for-14Consolidation
Ticker
Hamburg:471A
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hamburg
Currency
EUR

What changed lately

Latest news

All aTyr Pharma, Inc. news

aTyr Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 170 in all · newest Nov 19, 2026 · oldest 2019
Decks
24 decks · latest Jun 1, 2026

Where aTyr Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ATYR · Home listingNASDAQUnited StatesUSD
gettex:471AgettexGermanyEUR
Tradegate:471ATradegateGermanyEUR
LS Exchange:A2PM86LS ExchangeGermanyEUR
BOATS:ATYRBOATSUnited StatesUSD
Lang & Schwarz:A2PM86Lang & SchwarzGermanyEUR
Frankfurt:471AFrankfurtGermanyEUR
Hamburg:471A · This pageHamburgGermanyEUR
Munich:471AMunichGermanyEUR
Dusseldorf:471ADusseldorfGermanyEUR
Stuttgart:471AStuttgartGermanyEUR

Valuation

Price/book 0.3× against a median of 0.7×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$28.09M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
2.12

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
aTyr Pharma, Inc. · NASDAQ:ATYRUS$9.74M−US$28.09Mn/an/an/a0.3×n/a0.3×2.12
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
Lisata Therapeutics, Inc. · NASDAQ:LSTAUS$9.71M−US$273.0Mn/a−2,730×n/a1.3×n/a0.0×0.71
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Alzinova AB · OMXSTO:ALZUS$9.58MUS$8.35Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
Median of the othersUS$9.58MUS$4.33M0.1×−10.8×0.7×−303.7%0.0×0.88

Forecasts

1 strong buy · 2 buy · 6 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
45.17 USD · Analysts' mean
EPS, year to Dec 2026
-23.97 · 8 analysts

Team and board

Officers

OfficerRole
Sanjay S. ShuklaPresident and CEO, Director
Brandon YarasChief Financial Officer
Ashlee DunstonInvestor Relations and Public Affairs
Danielle CampbellVP, Human Resources
Leslie NangleVP, Research
Lisa CareyVP, Clinical Operations

Board

DirectorRole
Timothy P. CoughlinChairman
Eric BenevichDirector
Jane A. GrossDirector
Sanjay S. ShuklaPresident and CEO, Director
Sara L. ZaknoenDirector
Svetlana LucasDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+5.3%
Q2 2026Aug 7, 2026+5.4%
Q1 2026May 13, 2026+5.6%
Q4 2025Mar 5, 2026 · After close−8.7%
Q3 2025Nov 6, 2025 · After close+6.0%
Q2 2025Aug 7, 2025 · After close+1.1%
Q1 2025May 7, 2025 · After close+5.7%
Q4 2024Mar 12, 2025 · Before open+15.6%
Q3 2024Nov 7, 2024 · After close+0.7%
Q2 2024Aug 13, 2024 · After close+6.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close+0.6%
Q4 2023Mar 14, 2024 · After close+22.8%
Q3 2023Nov 9, 2023 · After close−2.6%
Q2 2023Aug 9, 2023 · After close0.0%
Q1 2023May 9, 2023 · After close+6.1%
Q4 2022Mar 9, 2023−8.7%
Q3 2022Nov 10, 2022 · After close+4.6%
Q2 2022Aug 15, 2022 · After close+14.0%
Q1 2022May 9, 2022 · After close−3.1%
Q4 2021Mar 14, 2022−9.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (June 2026)Investor deck27 slidesJun 1, 2026
Corporate Update (May 2026)Corporate update12 slidesMay 11, 2026
Technical Presentation (September 2025)Technical11 slidesSep 15, 2025
European Respiratory Society (ERS) Congress 2025Conference15 slidesSeptember 2025
Investor Presentation (September 2023)Investor deck21 slidesSep 26, 2023
Technical Presentation (May 2022)Technical32 slidesMay 17, 2022
Technical Presentation (September 2021)Technical13 slidesSep 13, 2021
European Respiratory Society International Congress 2021Conference14 slidesSep 7, 2021
Investor Presentation (January 2021)Investor deck32 slidesJan 11, 2021
Investor Presentation (May 2020)Investor deck31 slidesMay 18, 2020
All 24 decks
DeckKindSlidesDate
Investor Presentation (March 2019)Investor deck23 slidesMar 11, 2019
Investor Presentation (June 2018)Investor deck23 slidesJun 4, 2018
Investor Presentation (January 2018)Investor deck18 slidesJan 8, 2018
Investor Presentation (August 2017)Investor deck33 slidesAug 28, 2017
American Thoracic Society International Conference 2017Conference55 slidesMay 23, 2017
American Academy of Neurology 2017Conference32 slidesApr 24, 2017
Technical Presentation (April 2017)Technical6 slidesApr 24, 2017
Investor Presentation (January 2017)Investor deck37 slidesJan 9, 2017
Technical Presentation (December 2016)Technical49 slidesDec 13, 2016
Technical Presentation (December 2016)Technical18 slidesDec 13, 2016
Investor Presentation (November 2016)Investor deck39 slidesNov 7, 2016
Corporate Update (May 2016)Corporate update42 slidesMay 11, 2016
Investor Presentation (April 2016)Investor deck43 slidesApr 13, 2016
Investor Presentation (January 2016)Investor deck35 slidesJan 11, 2016

Open Decks

IPO

Priced at US$14.00 a share on May 6, 2015.

Price
US$14.00 a share
Shares offered
5,360,000 shares of common stock
Offering size
US$75 million
Underwriters
J.P. Morgan, Citigroup, BMO Capital Markets, William Blair · In the order on the cover
Shares delivered
On or about May 12, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceDec 22, 2014
Filed publiclyApr 6, 2015
Amended 3 timesNewest May 6, 2015
Shares registered with an exchangeMay 6, 2015
Declared effective by the SECMay 6, 2015
Final prospectus, with the priceMay 7, 2015

Open IPO · From the cover of the final prospectus (424B4) filed May 7, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue190.0K235.0K353.0K10.4M010.5M422.0K
Cost of revenue1.55M1.54M2.74M1.70M1.30M17.3M14.0M746.0K713.0K900.0K
Gross profit-1.36M235.0K353.0K8.69M-1.30M-6.84M-13.6M-746.0K-713.0K-900.0K
Research and development60.2M54.4M42.3M42.8M23.3M17.3M14.0M20.4M30.1M42.8M
Selling, general and administrative17.6M13.8M13.0M14.0M10.8M9.07M9.35M
Operating income-77.6M-67.9M-54.9M-46.4M-34.0M-15.9M-23.0M-32.8M-47.1M-57.9M
Depreciation and amortization664.0K708.0K592.0K232.0K475.0K569.0K635.0K746.0K713.0K900.0K
EBITDA-77.0M-67.2M-54.3M-46.2M-33.5M-15.3M-22.3M-32.1M-46.4M-57.0M
Income before tax-74.1M-64.0M-50.4M-45.3M-33.8M-16.2M-23.8M-34.5M-48.2M-57.9M
Income tax00000000-49.0K
Net income-74.1M-64.0M-50.4M-45.3M-33.8M-16.2M-16.2M-34.5M-48.2M-57.9M
Earnings per share, basic-0.80-0.86-0.94-1.60-1.77-1.77-7.03-16.11-26.13-2.44
Earnings per share, diluted-0.80-0.86-0.94-1.60-1.77-1.77-7.03-16.11-26.13-2.44

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents10.7M11.1M22.5M9.98M2.34M17.0M9.21M23.0M21.1M38.4M
Short-term investments67.9M61.1M75.6M56.2M105.6M14.7M21.9M26.6M64.0M33.8M
Receivables873.0K1.74M2.44M11.8M435.0K2.04M100.0K
Current assets80.2M82.0M103.0M80.9M113.6M35.5M31.9M50.8M87.0M74.8M
Property, plant and equipment4.26M4.85M5.53M3.06M543.0K899.0K1.27M1.85M2.28M1.42M
Total assets93.0M96.8M120.7M95.8M115.5M38.7M36.2M52.7M89.4M80.5M
Accounts payable3.89M4.32M3.53M3.11M1.03M1.43M847.0K1.04M2.28M2.61M
Current liabilities15.1M15.0M16.4M13.9M6.01M5.86M12.9M10.8M10.4M8.53M
Long-term debt8.26M14.7M9.20M
Total debt12.0M13.3M15.1M11.5M1.38M2.24M8.74M16.0M19.7M9.54M
Total liabilities26.9M27.0M30.2M24.5M6.41M7.24M15.2M19.1M25.1M17.7M
Shareholders' equity67.5M70.0M90.7M71.5M109.3M31.6M21.2M33.6M64.2M62.8M
Shares outstanding2.45M84.0M63.3M29.5M27.8M11.0M3.89M2.19M29.8M23.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-62.0M-69.1M-33.2M-41.9M-33.1M-15.3M-20.0M-31.1M-42.4M-52.9M
Capital spending-77.0K-65.0K-4.21M-1.64M-192.0K-202.0K-79.0K-594.0K-1.31M-600.0K
Free cash flow-62.1M-69.2M-37.4M-43.5M-33.3M-15.5M-20.1M-31.7M-43.7M-53.5M
Cash from investing-5.05M17.2M-20.1M47.2M-91.6M6.90M4.92M37.2M-27.6M33.5M
Cash from financing66.0M39.9M66.2M5.45M110.0M16.1M1.34M-4.24M52.7M4.70M
Change in cash-1.03M-12.0M12.9M10.8M-14.6M7.74M-13.8M1.87M-17.3M-14.6M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 13, 2026Current reportSEC
8-K · Current reportNov 6, 2026Current reportSEC
424B5 · ProspectusNov 6, 2026Offer documentSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 4, 2026Big-stake noticeSEC
8-K · Current reportOct 27, 2026Current reportSEC
8-K · Current reportOct 16, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2026Big-stake noticeSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipOct 1, 2026Insider tradeSEC
8-K · Current reportSep 24, 2026Current reportSEC
DEF 14A · Proxy statementSep 11, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementAug 31, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansAug 7, 2026Offer documentSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
8-K · Current reportAug 7, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
8-K · Current reportJul 31, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
8-K · Current reportJun 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 5, 2026Big-stake noticeSEC
8-K · Current reportJun 1, 2026Current reportSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
8-K · Current reportMay 11, 2026ResultsSEC
ARS · Annual report to shareholdersMar 26, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 26, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
DEF 14A · Proxy statementMar 26, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 12, 2026Meeting noticeSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
8-K · Current reportDec 5, 2025Current reportSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2025Big-stake noticeSEC
8-K · Current reportSep 15, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 19, 2025Other filingsSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2025Other filingsSEC
8-K/A · Current report, amendedAug 7, 2025ResultsSEC
S-8 · Registration statement for employee plansAug 7, 2025Offer documentSEC
S-3 · Registration statementAug 7, 2025Offer documentSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
8-K · Current reportMay 6, 2025Management or board changeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
ARS · Annual report to shareholdersMar 19, 2025Annual reportSEC
DEFA14A · Additional proxy materialMar 19, 2025Meeting noticeSEC
DEF 14A · Proxy statementMar 19, 2025Meeting noticeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2025Big-stake noticeSEC
424B5 · ProspectusDec 23, 2024Offer documentSEC
8-K · Current reportDec 23, 2024Material contractSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 12, 2024Insider tradeSEC
8-K · Current reportDec 12, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeOct 15, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 7, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 13, 2024Offer documentSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
4 · Change in ownershipJul 24, 2024Insider tradeSEC
8-K · Current reportJul 22, 2024Current reportSEC
UPLOAD · Letter from the SECJun 25, 2024Other filingsSEC
CORRESP · Letter to the SECJun 18, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 6, 2024Other filingsSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
4 · Change in ownershipJun 3, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Management or board changeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
4 · Change in ownershipMay 23, 2024Insider tradeSEC
10-Q · Quarterly reportMay 2, 2024Quarterly reportSEC
8-K · Current reportMay 2, 2024ResultsSEC
ARS · Annual report to shareholdersApr 5, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 5, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 5, 2024Meeting noticeSEC
10-K · Annual reportMar 14, 2024Annual reportSEC
8-K · Current reportMar 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
4 · Change in ownershipFeb 6, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 18, 2024Big-stake noticeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeJan 2, 2024Big-stake noticeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveNov 21, 2023Other filingsSEC
CORRESP · Letter to the SECNov 16, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 15, 2023Other filingsSEC
4 · Change in ownershipNov 13, 2023Insider tradeSEC
S-3 · Registration statementNov 9, 2023Offer documentSEC
424B5 · ProspectusNov 9, 2023Offer documentSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportSep 26, 2023Current reportSEC
8-K · Current reportSep 11, 2023Current reportSEC
S-8 · Registration statement for employee plansAug 10, 2023Offer documentSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 9, 2023ResultsSEC
4 · Change in ownershipAug 1, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
4 · Change in ownershipMay 19, 2023Insider tradeSEC
8-K · Current reportMay 19, 2023Management or board changeSEC
4 · Change in ownershipMay 11, 2023Insider tradeSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
8-K · Current reportMay 9, 2023ResultsSEC
4 · Change in ownershipApr 28, 2023Insider tradeSEC
4 · Change in ownershipApr 28, 2023Insider tradeSEC
4 · Change in ownershipApr 28, 2023Insider tradeSEC
4 · Change in ownershipApr 28, 2023Insider tradeSEC
4 · Change in ownershipApr 28, 2023Insider tradeSEC
4 · Change in ownershipApr 28, 2023Insider tradeSEC
ARS · Annual report to shareholdersApr 18, 2023Annual reportSEC
DEFA14A · Additional proxy materialMar 29, 2023Meeting noticeSEC
DEFA14A · Additional proxy materialMar 29, 2023Meeting noticeSEC
DEF 14A · Proxy statementMar 29, 2023Meeting noticeSEC
10-K · Annual reportMar 14, 2023Annual reportSEC
8-K · Current reportMar 10, 2023Current reportSEC
8-K · Current reportMar 9, 2023ResultsSEC
PRE 14A · Preliminary proxy statementMar 7, 2023Meeting noticeSEC
SC 13G · Big-stake noticeFeb 22, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 21, 2023Insider tradeSEC
4 · Change in ownershipFeb 21, 2023Insider tradeSEC
4 · Change in ownershipFeb 21, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 17, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
8-K · Current reportFeb 9, 2023Current reportSEC
424B5 · ProspectusFeb 9, 2023Offer documentSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
424B5 · ProspectusFeb 8, 2023Offer documentSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
4 · Change in ownershipFeb 6, 2023Insider tradeSEC
8-K · Current reportFeb 6, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 1, 2023Big-stake noticeSEC
4 · Change in ownershipNov 21, 2022Insider tradeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportNov 10, 2022ResultsSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportAug 15, 2022ResultsSEC
8-K · Current reportAug 11, 2022Current reportSEC
4 · Change in ownershipJul 6, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
4 · Change in ownershipMay 26, 2022Insider tradeSEC
8-K · Current reportMay 17, 2022Current reportSEC
8-K · Current reportMay 16, 2022Material contractSEC
S-8 · Registration statement for employee plansMay 11, 2022Offer documentSEC

This page holds 200 of 756 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from aTyr Pharma, Inc.’s releases

Common shares
2,549,230
Fully diluted
2,549,230

Fully diluted

LineShares
Common shares2,549,230

Share count over time

CountShares
Nov 22, 20262,549,230
Oct 27, 2026

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Federated Hermes, Inc.4.97MUS$1.5MSep 30, 2026
Vanguard4.38MUS$1.33MSep 30, 2026
Gsa Capital Partners LLP3.42MUS$1.04MSep 30, 2026
Kalehua Capital Management LLC1.83MUS$554KSep 30, 2026
Fidelity1.78MUS$540KSep 30, 2026
BlackRock1.62MUS$491KSep 30, 2026
Jacobs Levy Equity Management, Inc1.38MUS$418KSep 30, 2026
Geode Capital1.21MUS$366KSep 30, 2026
UBS1.17MUS$353KSep 30, 2026
Morgan Stanley1.1MUS$334KSep 30, 2026
Show 50 holders
HolderSharesValueAs of
AQR Capital Management LLC691KUS$209KSep 30, 2026
Millennium581KUS$176KSep 30, 2026
State Street482KUS$146KSep 30, 2026
Squarepoint Ops LLC401KUS$121KSep 30, 2026
Susquehanna315KUS$95,589Sep 30, 2026
Renaissance Technologies282KUS$85,301Sep 30, 2026
Two Sigma262KUS$79,248Sep 30, 2026
Bank of America224KUS$67,783Sep 30, 2026
Northern Trust218KUS$66,183Sep 30, 2026
Goldman Sachs177KUS$53,725Sep 30, 2026
Acadian Asset Management LLC126KUS$37,000Sep 30, 2026
StoneX Group Inc.105KUS$31,815Sep 30, 2026
LPL Financial LLC96,375US$29,202Sep 30, 2026
Group One Trading LLC89,492US$27,116Sep 30, 2026
BMO60,800US$18,422Sep 30, 2026
Kingswood Wealth Advisors, LLC52,000US$15,756Sep 30, 2026
Alpha Wealth Funds, LLC50,000US$15,385Sep 30, 2026
Qube Research & Technologies Ltd48,113US$14,578Sep 30, 2026
Hobbs Group Advisors, LLC35,992US$10,905Sep 30, 2026
Rockefeller Capital Management L.P.28,118US$8,520Sep 30, 2026
Barclays26,689US$8,087Sep 30, 2026
Steward Partners Investment Advisory, LLC23,600US$7,151Sep 30, 2026
HSBC22,214US$7,051Sep 30, 2026
Wealth Enhancement Advisory Services, LLC21,092US$5,385Sep 30, 2026
Mercer Global Advisors Inc20,948US$6,347Sep 30, 2026
Mariner, LLC20,619US$6,248Sep 30, 2026
Creative Planning16,842US$5,103Sep 30, 2026
Raymond James Financial Inc16,801US$5,091Sep 30, 2026
Certuity, LLC14,200US$4,303Sep 30, 2026
JPMorgan13,028US$4,009Sep 30, 2026
Captrust Financial Advisors12,223US$3,704Sep 30, 2026
Balyasny Asset Management L.P.10,380US$3,145Sep 30, 2026
Arax Advisory Partners9,949US$3,015Sep 30, 2026
Nuveen9,515US$5,389Sep 30, 2026
RBC5,868US$2,000Sep 30, 2026
Optiver Holding B.V.5,716US$1,732Sep 30, 2026
BNP Paribas4,097US$1,241Sep 30, 2026
Wells Fargo4,000US$1,213Sep 30, 2026
Allworth Financial LP2,032US$616Sep 30, 2026
Ares Financial Consulting, LLC2,000US$606Sep 30, 2026

This page holds 50 of 67 holders. Open Shareholders

Funds

HolderSharesValueAs of
Federated Hermes Kaufmann Fund4.37MUS$2.12MJul 31, 2026
Fidelity Growth Company Fund4.22MUS$2.29MMay 31, 2026
Federated Hermes Kaufmann Small Cap Fund4.06MUS$1.97MJul 31, 2026
Vanguard Total Stock Market Index Fund2.65MUS$1.58MJun 30, 2026
Select Biotechnology Portfolio1.75MUS$952KMay 31, 2026
Vanguard Extended Market Index Fund1.05MUS$629KJun 30, 2026
Fidelity Extended Market Index Fund550KUS$298KMay 31, 2026
Vanguard Russell 2000 Index Fund489KUS$265KMay 31, 2026
Fidelity Total Market Index Fund168KUS$91,203May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF146KUS$87,149Jun 30, 2026
All 42 holders
HolderSharesValueAs of
Fidelity Series Total Market Index Fund145KUS$78,857May 31, 2026
Vanguard Russell 2000 Growth Index Fund85,881US$46,590May 31, 2026
Federated Hermes Kaufmann Fund II81,100US$48,400Jun 30, 2026
Fidelity Nasdaq Composite Index Fund66,669US$36,168May 31, 2026
Goldman Sachs Absolute Return Tracker Fund66,034US$39,409Jun 30, 2026
Vanguard Balanced Index Fund56,767US$33,879Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund45,980US$27,441Jun 30, 2026
Fidelity ZERO Total Market Index Fund43,133US$20,950Jul 31, 2026
Fidelity ZERO Extended Market Index Fund35,230US$17,111Jul 31, 2026
Small Cap Index Fund33,620US$18,239May 31, 2026
Fidelity Flex Small Cap Index Fund19,962US$9,696Jul 31, 2026
Diversified Equity Alpha Master Portfolio18,223US$10,875Jun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund15,897US$9,487Jun 30, 2026
Siit Extended Market Index Fund13,000US$7,053May 31, 2026
Blackstone Alternative Multi-Strategy Fund12,600US$7,520Jun 30, 2026
Vanguard Russell 3000 Index Fund7,366US$3,996May 31, 2026
VIP Extended Market Index Portfolio6,112US$3,648Jun 30, 2026
Strategic Equity Allocation Trust5,440US$3,247Jun 30, 2026
Vanguard Russell 2000 Value Index Fund4,561US$2,474May 31, 2026
AST Small-Cap Equity Portfolio4,540US$2,709Jun 30, 2026
Morgan Stanley Pathway Small-Mid Cap Equity ETF4,536US$2,461May 31, 2026
ProShares Russell 2000 High Income ETF4,514US$2,449May 31, 2026
JNL/DFA U.S. Small Cap Fund4,145US$2,474Jun 30, 2026
ProShares UltraPro Russell20003,569US$1,936May 31, 2026
ProShares Ultra Russell20003,530US$1,915May 31, 2026
State Street Balanced Index Fund3,393US$2,025Jun 30, 2026
Bridge Builder Small/Mid Cap Value Fund3,307US$1,974Jun 30, 2026
Destinations Small-Mid Cap Equity Fund2,610US$1,416May 31, 2026
VIP Total Market Index Portfolio2,051US$1,224Jun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND537US$261Jul 31, 2026
ProShares Hedge Replication ETF90US$49May 31, 2026
ProShares Russell 2000 Dynamic Buffer ETF28US$15May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Schimmel Paul
Director
Buy100,000USD 0.50US$50,000May 27, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kathryn Falberg
Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past)
Director · May 6, 2015 – May 24, 2016 · Past
Amir Nashat
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Scholar Rock Holding Corporation (Director · May 23, 2018 – May 9, 2024 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 1, 2022 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 14, 2019 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jul 31, 2019 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 9, 2015 · Past); Receptos Inc (Director · May 8, 2013 – Jun 3, 2014 · Past)
Director · May 6, 2015 – May 15, 2018 · Past
James C Blair
Other companies: Clovis Oncology Inc (Director · Nov 15, 2011 – Jun 10, 2021 · Past); Zogenix Inc (Director · Nov 22, 2010 – May 21, 2014 · Past); Cadence Pharmaceuticals Inc (Director · Oct 24, 2006 – Mar 19, 2014 · Past); Volcano Corp (Director · Jun 14, 2006 – Apr 24, 2008 · Past); Paratek Pharmaceuticals Inc (Director · May 9, 2006 – Jun 6, 2007 · Past); Pharmion Corp (Director · May 1, 2006 – Mar 7, 2008 · Past); NuVasive Inc (Director · Mar 3, 2006 – May 24, 2007 · Past)
Director · May 6, 2015 – May 8, 2019 · Past
Jeffrey S. Hatfield
Other companies: Vir Biotechnology, Inc. (Chair of the Board · Since at least Dec 9, 2020); Larimar Therapeutics, Inc. (Chief Executive Officer, Director · Oct 9, 2017 – Jan 22, 2019 · Past); Viridian Therapeutics, Inc. (Director · Aug 10, 2017 – Feb 4, 2021 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 1, 2016 – Jan 19, 2018 · Past); Vitae Pharmaceuticals Inc (Chief Executive Officer, Director · Sep 24, 2014 – Oct 24, 2016 · Past); Ambit Biosciences Corp (Director · Jun 2, 2014 – Nov 10, 2014 · Past)
Director · Apr 3, 2017 – May 6, 2020 · Past
Mark Alan Goldberg
Other companies: Blueprint Medicines Corp (Director · Since at least Jun 25, 2015); Audentes Therapeutics Inc (Director · Dec 11, 2017 – Jan 15, 2020 · Past); Crescent Biopharma, Inc. (Director · Jul 8, 2014 – May 1, 2024 · Past); Aceragen Inc. (Director · Jan 7, 2014 – Jun 23, 2022 · Past); ImmunoGen Inc (Director · Nov 8, 2011 – Feb 12, 2024 · Past); Synageva BioPharma Corp (EVP, Medical & Reg. Strategy · Nov 2, 2011 – Sep 19, 2014 · Past)
Director · May 6, 2015 – May 9, 2017 · Past
John K Clarke
Other companies: Verastem, Inc. (Director · Jan 26, 2012 – Jun 12, 2013 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 29, 2007 · Past); Momenta Pharmaceuticals Inc (Director · Jun 15, 2006 – Jun 10, 2015 · Past); Alnylam Pharmaceuticals, Inc. (Director · Jun 1, 2006 – Jun 20, 2018 · Past); Visicu Inc (Director · Apr 4, 2006 – Feb 20, 2008 · Past)
Director · May 6, 2015 – May 22, 2024 · Past
Paul Schimmel
Other companies: Alnylam Pharmaceuticals, Inc. (Co-founder and member of the Board of Directors · Since at least Jan 31, 2006); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – Nov 30, 2007 · Past); Repligen Corporation (Director · Aug 11, 2006 – Jun 14, 2007 · Past); Alkermes plc (Director · Mar 2, 2006 – Jun 15, 2007 · Past)
Director · Since at least May 6, 2015
Timothy P. Coughlin
Other companies: Vir Biotechnology, Inc. (Director · Since Jun 9, 2026); ADC Therapeutics SA (Director · Since at least Jun 3, 2025); Travere Therapeutics, Inc. (Director · Since at least Mar 31, 2015); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Jun 7, 2024 · Past); Neurocrine Biosciences, Inc. (Chief Financial Officer · Sep 18, 2006 – Feb 6, 2017 · Past)
Chairman · Since at least Apr 7, 2017
Jill Marie Broadfoot
Other companies: Cue Biopharma, Inc. (Director · Since at least Jun 4, 2025); Talphera, Inc. (Director · Since at least Nov 20, 2021); Otonomy Inc (Director · Aug 18, 2021 – Jun 21, 2022 · Past); Vical Incorporated (Sr Vice President, CFO, Sec · Jan 7, 2011 – Apr 1, 2013 · Past)
Chief Financial Officer · Since at least Jul 30, 2018
John Mendlein
Other companies: Fate Therapeutics, Inc. (Director · Since at least Sep 30, 2013); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 20, 2024 · Past); Moderna, Inc. (See Remarks · Dec 7, 2018 – Dec 7, 2018 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Jun 15, 2017 · Past)
Director · May 6, 2015 – May 8, 2019 · Past
All 29 people
PersonSeat
Jane A. Gross
Other companies: BriaCell Therapeutics Corp (Director of the Board · Since at least Aug 1, 2022); Aptevo Therapeutics Inc. (SVP & Chief Scientific Officer · Sep 1, 2016 – Jan 29, 2021 · Past)
Director · Since at least Jun 28, 2019
Svetlana Lucas
Other companies: Scribe Therapeutics Inc. (Chief Business Officer · Since at least Mar 13, 2026); Jasper Therapeutics, Inc. (Board Member · Since at least Jun 18, 2024)
Director · Since at least Jun 28, 2019
Eric Benevich
Other companies: Neurocrine Biosciences, Inc. (Chief Commercial Officer · Since at least May 26, 2015)
Director · Since at least Dec 10, 2024
John T Blake
Other companies: Vivani Medical, Inc. (Chief Financial Officer · Mar 26, 2018 – Feb 19, 2020 · Past)
Senior Vice President, Finance · Oct 28, 2015 – Feb 6, 2018 · Past
Kelly Blackburn
Other companies: CervoMed Inc. (Executive Vice President, Clinical Development · Since at least Aug 16, 2023)
VP, Clinical Affairs · May 6, 2015 – Mar 28, 2016 · Past
Andrew CubittVP, Product Protection · May 6, 2015 – Sep 13, 2016 · Past
Ashlee DunstonInvestor Relations and Public Affairs · Since at least Oct 29, 2026
Brandon YarasChief Financial Officer · Since at least Aug 10, 2026
Danielle CampbellVP, Human Resources · Since at least Nov 5, 2026
David John KingChief Scientific Officer · Sep 21, 2016 – Feb 6, 2018 · Past
Fred RamsdellVP, Immunology · May 6, 2015 – Oct 1, 2015 · Past
Leslie NangleVP, Research · Since at least Oct 13, 2026
Lisa CareyVP, Clinical Operations · Since at least Sep 30, 2025
Melissa A AshlockSee Remarks · May 6, 2015 – Jan 27, 2016 · Past
Nancy DenyesGeneral Counsel · Since at least Jan 5, 2024
Sanjay S. ShuklaPresident and CEO, Director · Since at least Mar 30, 2016
Sanuj K RavindranChief Business Officer · Jan 4, 2016 – Feb 7, 2017 · Past
Sara L. ZaknoenDirector · Since at least May 21, 2021
Stan BlackburnActing Chief Financial Officer · May 6, 2015 – Jan 27, 2016 · Past

Open People

Log in to ask 6ix AI your own questions about aTyr Pharma, Inc.